(VIANEWS) – Equus Total Return (EQS), Moelis & Company (MC), Ligand Pharmaceuticals Incorporated (LGND) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Equus Total Return (EQS)
139.2% sales growth and 21.46% return on equity
Equus Total Return, Inc. is a business development company (BDC) specializing in leveraged buyouts, management buyouts, corporate partnerships/joint ventures, growth and expansion capital, acquisition financing, roll-up acquisition strategies, operational turnarounds, recapitalizations of existing businesses, special situations, equity and equity-oriented securities issued by privately owned companies, debt securities including subordinate debt, debt convertible into common or preferred stock, or debt combined with warrants and common and preferred stock, and preferred equity financing. It invests in small to mid-sized companies and acts as a lead investor. It invests in technology, telecommunication, financial services, natural resource and industrial manufacturing and services. It invests in companies engaged in the alternative energy, real estate, healthcare, education, e-learning, leisure and entertainment, and foreign investment sector in the United States, China, India, and Europe. It investments include common and preferred stock, debt convertible into common or preferred stock, debt combined with warrants and options, and other rights to acquire common or preferred stock. It seeks to invest in companies between $1 million to $25 million with revenues between $5 million and $150 million with EBITDA between $2 million to $50 million. It seeks to take control and non-control equity positions. Equus Total Return, Inc. was founded in 1991 and is based in Houston, Texas with additional office in Vancouver, Canada.
Earnings Per Share
As for profitability, Equus Total Return has a trailing twelve months EPS of $0.71.
PE Ratio
Equus Total Return has a trailing twelve months price to earnings ratio of 1.9. Meaning, the purchaser of the share is investing $1.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.46%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2658.3%, now sitting on 845k for the twelve trailing months.
Sales Growth
Equus Total Return’s sales growth is 139.2% for the present quarter and 139.2% for the next.
Volume
Today’s last reported volume for Equus Total Return is 12151 which is 18.98% above its average volume of 10212.
Yearly Top and Bottom Value
Equus Total Return’s stock is valued at $1.35 at 11:22 EST, way below its 52-week high of $1.95 and way higher than its 52-week low of $1.19.
2. Moelis & Company (MC)
50.8% sales growth and 3.69% return on equity
Moelis & Company, an investment bank, provides strategic and financial advisory services in the United States and internationally. It advises clients in the areas of mergers and acquisitions, recapitalizations and restructurings, capital markets advisory, and other corporate finance matters. The company offers its services to public multinational corporations, governments, financial sponsors, middle market private companies, and individual entrepreneurs. It has strategic alliances with Sumitomo Mitsui Banking Corporation and SMBC Nikko Securities Inc.; and Alfaro, Dávila y Scherer, S.C. The company was founded in 2007 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Moelis & Company has a trailing twelve months EPS of $0.15.
PE Ratio
Moelis & Company has a trailing twelve months price to earnings ratio of 455.73. Meaning, the purchaser of the share is investing $455.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.69%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 260% and 783.3%, respectively.
3. Ligand Pharmaceuticals Incorporated (LGND)
49.9% sales growth and 5.85% return on equity
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
Earnings Per Share
As for profitability, Ligand Pharmaceuticals Incorporated has a trailing twelve months EPS of $2.33.
PE Ratio
Ligand Pharmaceuticals Incorporated has a trailing twelve months price to earnings ratio of 45.41. Meaning, the purchaser of the share is investing $45.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.85%.
Sales Growth
Ligand Pharmaceuticals Incorporated’s sales growth for the next quarter is 49.9%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 31.4% and 4.3%, respectively.
Yearly Top and Bottom Value
Ligand Pharmaceuticals Incorporated’s stock is valued at $105.80 at 11:22 EST, below its 52-week high of $112.13 and way above its 52-week low of $49.24.
4. MFA Financial (MFA)
37.5% sales growth and 5.14% return on equity
MFA Financial, Inc., together with its subsidiaries, operates as a real estate investment trust in the United States. The company invests in residential mortgage assets, including non-agency mortgage-backed securities, agency MBS, and credit risk transfer securities; residential whole loans, including purchased performing loans, purchased credit deteriorated, and non-performing loans; and mortgage servicing rights related assets. MFA Financial, Inc. was incorporated in 1997 and is based in New York, New York.
Earnings Per Share
As for profitability, MFA Financial has a trailing twelve months EPS of $0.63.
PE Ratio
MFA Financial has a trailing twelve months price to earnings ratio of 19.21. Meaning, the purchaser of the share is investing $19.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.14%.
Sales Growth
MFA Financial’s sales growth is 35% for the current quarter and 37.5% for the next.
Volume
Today’s last reported volume for MFA Financial is 527187 which is 27.89% below its average volume of 731142.
Moving Average
MFA Financial’s worth is higher than its 50-day moving average of $11.20 and higher than its 200-day moving average of $11.02.
Yearly Top and Bottom Value
MFA Financial’s stock is valued at $12.10 at 11:22 EST, below its 52-week high of $12.31 and way higher than its 52-week low of $8.41.
5. Woodward (WWD)
8.6% sales growth and 17.54% return on equity
Woodward, Inc. designs, manufactures, and services control solutions for the aerospace and industrial markets worldwide. The company operates in two segments, Aerospace and Industrial. The Aerospace segment provides fuel pumps, metering units, actuators, air valves, specialty valves, fuel nozzles, and thrust reverser actuation systems for turbine engines and nacelles, and flight deck controls, actuators, servocontrols, motors, and sensors for aircraft. These products are used on commercial and private aircraft and rotorcraft, as well as on military fixed-wing aircraft and rotorcraft, guided weapons, and other defense systems. It also provides aftermarket maintenance, repair and overhaul, and other services to commercial airlines, repair facilities, military depots, third party repair shops, and other end users. This segment sells its products to original equipment manufacturers (OEMs), tier-one suppliers, and contractors, as well as through aftermarket sales of components, such as provisioning spares and replacements. The Industrial segment offers actuators, valves, pumps, fuel injection systems, solenoids, ignition systems, speed controls, electronics and software, and sensors. These products are used on industrial gas turbines, steam turbines, compressors, and reciprocating engines. This segment sells its aftermarket products, and other related services to OEMs through an independent network of distributors, as well as directly to end users. The company was founded in 1870 and is headquartered in Fort Collins, Colorado.
Earnings Per Share
As for profitability, Woodward has a trailing twelve months EPS of $5.99.
PE Ratio
Woodward has a trailing twelve months price to earnings ratio of 25.99. Meaning, the purchaser of the share is investing $25.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.54%.
Volume
Today’s last reported volume for Woodward is 280183 which is 38.37% below its average volume of 454679.
Sales Growth
Woodward’s sales growth is 4.6% for the present quarter and 8.6% for the next.
6. Manhattan Associates (MANH)
7.9% sales growth and 99.58% return on equity
Manhattan Associates, Inc. develops, sells, deploys, services, and maintains software solutions to manage supply chains, inventory, and omni-channel operations. It offers Manhattan SCALE, a portfolio of logistics execution solutions that provide trading partner management, yard management, optimization, warehouse management, and transportation execution services; and Manhattan Active, a set of enterprise and omnichannel solution, which include enterprise solutions and omnichannel solutions for store. The company also provides inventory optimization, planning, and allocation solutions; technology platform including Manhattan Active Platform solutions, a cloud-native product designed to provide version-less product access; maintenance services, which offers comprehensive program that provides on-premises software licensees with software upgrades for additional or improved functionality and technological advances incorporating emerging supply chain and industry advances; and professional services, such as solutions planning and implementation, and related consulting services. In addition, it provides training and change management services; resells computer hardware, radio frequency terminal networks, radio frequency identification chip readers, bar code printers and scanners, and other peripherals. Further, the company offers products through direct sales personnel, as well as through partnership agreements with various organizations. It serves retail, consumer goods, food and grocery, logistics service providers, industrial and wholesale, high technology and electronics, life sciences, and government industries. The company operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Manhattan Associates, Inc. was founded in 1990 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Manhattan Associates has a trailing twelve months EPS of $3.28.
PE Ratio
Manhattan Associates has a trailing twelve months price to earnings ratio of 80.62. Meaning, the purchaser of the share is investing $80.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 99.58%.
Volume
Today’s last reported volume for Manhattan Associates is 491666 which is 11.37% above its average volume of 441469.
Moving Average
Manhattan Associates’s value is higher than its 50-day moving average of $247.12 and way above its 200-day moving average of $233.99.
